J Korean Geriatr Psychiatry.
2025 Oct;29(2):84-88. 10.47825/jkgp.2025.29.2.84.
Case Report on Clinical Features Within Six Months of Lecanemab Use
- Choo IH
1,2
- Affiliations
-
- 1Department of Neuropsychiatry, College of Medicine, Chosun University, Gwangju, Korea
- 2Department of Psychiatry, Chosun University Hospital, Gwangju, Korea
- KMID: 2573894
- DOI: http://doi.org/10.47825/jkgp.2025.29.2.84
Abstract
- Lecanemab is a humanized monoclonal antibody that binds with high affinity to soluble amyloid-beta protofibrils and was ap- proved by the FDA on July 6, 2023. This case report describes the clinical setting for lecanemab administration, as well as the clinical course and adverse events following six months of treatment in four patients with Alzheimer’s disease dementia. These findings may serve as foundational information for future clinical practice and research involving monoclonal antibody therapies for Alzheimer’s disease.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Demographic, Social, and Clinical Profiles of Patients Initiating Lecanemab in Clinical Practice: A Single-Center Experience in Korea
- Shifting the Paradigm of Dementia Management in Korea with the Role of Lecanemab
- Baseline Clinical and Neuropsychological Characteristics of Amyloid PET-Confirmed Alzheimer’s Disease Treated With Lecanemab: Early Experience at a Tertiary Hospital in Korea
- Stage-Specific Efficacy of Lecanemab and Donanemab in Early Alzheimer’s Disease: An Indirect, Comparative Interpretation of Phase 3 Trials
- The Developmental Journey and Recent Clinical Advances of Anti-Amyloid Therapies in Alzheimer’s Disease
